This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Reimagining the Long-Term Pharmacy

Curenta - is an online pharmacy serving long-term care providers. Curenta is reimagining pharmacy, one vertical at a time. Long-term care is a forgotten vertical with its unique complexity where Curenta is solving communication and delivery issues between facilities and pharmacies. With the network of stores, Curenta can turn around orders in an astounding 3 hours, saving money on unused medications and wasted nurses’ time.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$101,131.92 Raised

Reasons to Invest

  • Curenta re-imagines the long-term pharmacy industry by challenging its core components and up-scaling its service level while saving on operations costs.
  • Long-term care (LTC) consumes more than US $23 billion of medications annually and is growing at a staggering 6.8% a year.  We have grown by 7x in the last 12 months. In our first year of operations, we have made almost US $3.59 Million in annualized sales (ARR) as of Dec 2021. (2021 figures unaudited, preliminary, and subject to change)
  • Key investors and Advisors include
    • Amir Barsoum; A serial entrepreneur who built one of the biggest global digital healthcare companies operating in 10 countries serving more than 20 million patients. 
    • Ihab Dorotta; Chief, quality, and patient safety officer of Loma Linda University Hospital (LLUH), was chosen as one of the top 50 patient safety experts to know in the country by Becker’s and the best in the inland empire. Has extensive experience in the long-term care space. 


Curenta: Reimagining the Long-term Pharmacy

Curenta helps long-term care facilities with their overworked nurses by taking the pain out of the medication management process.

Our proprietary technology streamlines it all - from receiving the orders, to the preparation of medication, to the delivery - we operate with complete transparency of the steps.

We’re here to reduce wasted time, energy, and money in the process. 

This means:

  • Reduced workload for the facility nurses by 50%
  • Improved nurse/prescriber relationship by eliminating the need for frequent phone calls
  • Eliminated pharmacy mistakes which results in fewer medication errors
  • Improved communication between the prescriber and the pharmacy which results in faster delivery
  • Increased patient satisfaction since they receive their medications faster and more reliably

The Problem

Lots of Issues When it Comes to Long-term Care Resources

This is why we’ve narrowed our target issues to these main factors:


Not to mention, outdated communication tools with pharmacies along with delayed medication delivery forces facilities to have unnecessary costs along with increased patients’ dissatisfaction.

THE Market

Long-term Pharmacy Market is on the Rise

And that means our market size is $23 billion, with a CAGR of 6.8%

Here’s why:


The Solution

Say Hello to Connected APIs and On-Demand Delivery

We are a meds management tool and connected-APIs pharmacy network - coupled with on-demand delivery to turnaround in just 3-4 hours.

Let’s walk through what that looks like:

A facility uses our medication management tool to order medications for their patients, all to reduce the chance of medication errors while saving time.

Once the pharmacy receives the orders, our system organizes and sorts them based on our proprietary AI Algorithm to make sure that everyone involved in preparing the medications knows which orders they should be working on first.

As the pharmacies’ teams prepare the medications, the delivery app creates routes automatically considering the 3-hours delivery turnaround time, traffic, delivery address, and pushes notifications to our on-demand fleet of drivers, and whoever accepts the route picks up the medication from that store, and delivers the medications.

Curenta has been a huge asset for any facility in terms of visibility and efficiency. The entire operation is streamlined, which means that physicians, nurses, and med-techs have more time to spend on patient care rather than administrative tasks.

Curenta’s unique features make it easy to manage all aspects of the prescription fulfillment:

  1. Check patient medication history
  2. Submit prescriptions through the platform
  3. Track each order as it moves through the system

There are a few reasons why we stand out against the crowd.

1. Curenta has speeded up most of the processes for the nurses and the pharmacy, using automation and AI in the ordering, billing, filling and shipping processes, resulting in high patients’ satisfaction. While in today’s traditional pharmacy most of the orders are still communicated through faxes, resulting in high rates of medication errors and late deliveries. (Source)

2. After the pandemic, nursing staff and caregivers are often overwhelmed by all the tasks they must do on a daily basis to ensure that their patients receive the proper care they require. Instead of communicating manually with pharmacists, doctors, and hospitals, we can now automate these processes by using an online prescription ordering system, saving them a lot of time that was previously wasted. (Source, Source)

3. The traditional pharmacy operations are always hidden, no one from the facility side knows anything about their orders unless the pharmacy teams are proactively communicating with the facility. This is not the case with Curenta, where every single step through the process is trackable with full transparency. Nurses and patients can easily track their prescriptions, communicate with the pharmacy team, know the delivery ETA (estimated time of arrival) without calling or spending their precious time trying to figure it.

We make money through dispensing medications to LTC facilities and hospices from our own stores, and network of stores.

Why Invest

Our Vision: To Re-imagine The Pharmacy

In today’s world, where technology plays an important role, there are multiple processes involved in medication management that can be automated using our software applications. These include prescription processing, dispensing, inventory management, patient engagement, etc. 

As we look forward, we want to be able to connect our customers; facilities, and patients to a decentralized marketplace where their orders go straight to the closest Curenta store with available stock and automatically bill their prescriptions using artificial intelligence (AI). It could improve efficiency, accuracy, and cut down on medication errors (48% in normal cases), and speed up things for pharmacies and nurses.

Our vision is to build a fully automated network of stores, all connected by our technology, to serve the elderly population with fast, simple, and affordable services. 

We have already poised ourselves to be a great market fit, which is reflected in the hyper-growth rate of $3.59 million in ARR we have already hit in our first 12 months.*

The next milestone is to execute the business plan by having more stores owned by Curenta to cover different geographical locations and making sure of the fulfillment side. This also means the implementation of “Dark Pharmacies” concept meaning a network of Pharmacies owned and managed by other pharmacists to expand our market share in a faster way.

*Please note these financials have not been audited or reviewed by our CPA and are subject to change. Please refer to the risk factors of our offering materials. 

We are ready for takeoff in the pharmacy industry. We’re here to utilize the technology of today, and implement these systems which have historically lacked such tools. We want to make life easier for patients, nurses, and pharmacies alike. 

Join us on our mission!


23141 Verdugo Dr, Suite 103
Laguna Hills, CA 92653

Curenta - is an online pharmacy serving long-term care providers. Curenta is reimagining pharmacy, one vertical at a time. Long-term care is a forgotten vertical with its unique complexity where Curenta is solving communication and delivery issues between facilities and pharmacies. With the network of stores, Curenta can turn around orders in an astounding 3 hours, saving money on unused medications and wasted nurses’ time.


Ramy Barsoum Mikhail

Ramy Barsoum Mikhail

Chief Executive Officer

Licensed Pharmacist / MBA Maastricht School of Management

A CA licensed pharmacist and MBA degree holder from MsM with 15+ years of experience in retail and Long-Term Care pharmacies & 5 years leading a 12 pharmacies-consortium focusing on long-term care, serving 15,000 beds.

Ryan Soo Hoo

Ryan Soo Hoo

Director of Business Development

PharmD / University of Health Sciences and Pharmacy in St. Louis

A CA licensed PharmD and published clinical oncology researcher with pharmacy enterprise sales experience, focused on novel oncology drug-delivery systems. Utilizing his insight and experience in inpatient and outpatient pharmacy, Ryan is leading the team in building foundational business strategies with Long-Term Care facilities and Treatment Centers.

Ghada ElWahsh

Ghada ElWahsh

Head of Product

Built one of the first online pharmacies in the MENA region. A product enthusiast with 7 years journey in health tech product management. Leading product in Curenta for the supply and demand sides.

Nancy Yani

Nancy Yani

Operations Manager

A CA licensed pharmacist with 5 years experience in pharmacies operations management. Nancy used to run a group of retail and long-term care pharmacies, serving 2,000 beds.

Armstrong Chu

Armstrong Chu

Pharmacist In Charge (PIC)

PharmD / Notre Dame of Maryland University

A CA licensed PharmD with 5 years long-term care pharmacy experience. Armstrong is leading the pharmacy team in the daily interactions with the Long-Term Care facilities.

Amir Barsoum Mikhail

Amir Barsoum Mikhail


Amir Barsoum is the Founder and CEO of Vezeeta, a leading digital healthcare platform that offers patients a personalized, end-to-end healthcare experience from diagnosis to delivery of ongoing care and medications. Recognized as one of Fortune’s 40 under 40 global healthcare leaders in 2020, Amir helped pave the path for Vezeeta to become one of the fastest-growing health tech start-ups in the Middle East and Africa region and guided the expansion within the B2B landscape, with a growing footprint in North America, and Southeast Asia. Barsoum has helped shape the greater business community as an active angel investor and mentor for start-ups around the globe. He currently sits on the Board of three digital healthcare start-ups in the US, that focus on long-term care, revenue cycle management, and AI diagnostics. He is also a member of the Board of directors of Endeavor Egypt, and Entrepreneurs' Org, and offers guidance and consultations to major international institutions such as Bloomberg Health Council, Forbes Business Council, Endeavor, and MIT Legatum Centre. Prior to founding Vezeeta, he served as a Managing Consultant at McKinsey & Co. across Europe, and the Middle East region, and also held the position of Head of Strategic Planning at AstraZeneca. A pharmacist by education, Barsoum holds an MBA from MIT Sloan School of Management.

Mario Karras

Mario Karras

Board Observer

Mario specializes in M&A and international tax planning. During his time at Loyola Law School, Los Angeles, Mario was a member of the International Law Review and the Honors Tax Policy Colloquium. He also holds a B.B.A. from Emory University's Goizueta Business School in Finance, Strategy Management, and Entrepreneurship.


May 1, 2022
$10k - $1.07M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Early Bird

Friends and Family - First 72 hours | 15% bonus shares

Super Early Bird - Next 72 hours | 10% bonus

Early Bird Bonus - Next 7 days | 5% bonus shares



Tier 1 perk - (Invest $1000+ and receive 5% bonus shares)

Tier 2 perk - (Invest $2,500+ and receive 10% bonus shares)

Tier 3 perk - (Invest $5,000+ and receive 15% bonus shares and membership in our Investor Club which allows you to receive special investor updates, and attend Q&A sessions)

Tier 4 perk - (Invest $10,000+ and receive 15% bonus shares and membership in our Investor Club and an in-person meeting with the leadership team).

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Curenta Enterprise Corp. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $16/share, you will receive 110 Common Stock, meaning you'll own 110 shares for $1,600. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.


Article Image
FOX 40

Curenta, Introduces the First Automation in Medication Management with 400 Hospices & LTC Facilities

Article Image

Curenta, Introduces the First Automation in Medication Management with 400 Hospices & LTC Facilities

Article Image
Orange County OC Startup Council

Curenta is revolutionizing long-term care medication management. With their end-to-end API-connected solutions, they streamline the process, reduce costs, save time and improve quality. From medication ordering to delivery, with a turnaround in 4 hours.

Article Image

Curenta, Introduces the First Automation in Medication Management with 400 Hospices & LTC Facilities



Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Curenta.



Youssef Fawzy

2 years ago

Congrats on ur CF campaign launch, actually I was thinking to invest in NowRx but found your growth potential is more promising, also joining in the early bird stage makes the opportunity more appealing.



Kirtson Thompson

2 years ago

You mentioned that you need 23 stores to fully target your intended market starting from 1 already in 2021. Do you have an alternative strategy to accelerate buildout of the store roofline BEFORE 2025? If it is a question of funding VCs ca easily facilitate this fast runway. I guess my question is why reg CF at this point when you have ARR of $3.5MM already and poised to grow.



Kirtson Thompson

2 years ago

I definitely like the potential here however my major concern here is the amount of dilution in future given this is Reg CF at $16/share common equity. Any protections for us early potential investors?



Michael Asare-Sawiri

2 years ago

Can you put out a short video to explain EXACTLY what you do? How does Curenta make fast delivery? What exactly do you do?



Adam Forster

2 years ago

Hello. Since 1Q21, revenue per facility seems to be declining, Why? If you are able to deliver drugs so timely, why are you limiting your target market to LT Care? Thanks.



Girish Amin

2 years ago

Congrate on ur CF campaign launch on SE. I like what I see. What is your view on NowRx in competitive landscape? I don't see them listed in your chart. Thanks!



Benjamin Landman

2 years ago

Are 2021 Financials available? If not yet, when will they be available? How can we obtain a copy?




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.